233 related articles for article (PubMed ID: 12472287)
1. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
Sheffield MV; Yee H; Dorvault CC; Weilbaecher KN; Eltoum IA; Siegal GP; Fisher DE; Chhieng DC
Am J Clin Pathol; 2002 Dec; 118(6):930-6. PubMed ID: 12472287
[TBL] [Abstract][Full Text] [Related]
2. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of necrotic malignant melanomas.
Nonaka D; Laser J; Tucker R; Melamed J
Am J Clin Pathol; 2007 May; 127(5):787-91. PubMed ID: 17439838
[TBL] [Abstract][Full Text] [Related]
4. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.
Morris LG; Wen YH; Nonaka D; DeLacure MD; Kutler DI; Huan Y; Wang BY
Head Neck; 2008 Jun; 30(6):771-5. PubMed ID: 18228523
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections.
Kaufmann O; Koch S; Burghardt J; Audring H; Dietel M
Mod Pathol; 1998 Aug; 11(8):740-6. PubMed ID: 9720502
[TBL] [Abstract][Full Text] [Related]
6. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma.
Busam KJ; Iversen K; Coplan KC; Jungbluth AA
Am J Surg Pathol; 2001 Feb; 25(2):197-204. PubMed ID: 11176068
[TBL] [Abstract][Full Text] [Related]
7. Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.
Dorvault CC; Weilbaecher KN; Yee H; Fisher DE; Chiriboga LA; Xu Y; Chhieng DC
Cancer; 2001 Oct; 93(5):337-43. PubMed ID: 11668469
[TBL] [Abstract][Full Text] [Related]
8. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas.
Yu CH; Chen HH; Liu CM; Jeng YM; Wang JT; Wang YP; Liu BY; Sun A; Chiang CP
J Oral Pathol Med; 2005 Oct; 34(9):540-5. PubMed ID: 16138892
[TBL] [Abstract][Full Text] [Related]
9. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.
King R; Weilbaecher KN; McGill G; Cooley E; Mihm M; Fisher DE
Am J Pathol; 1999 Sep; 155(3):731-8. PubMed ID: 10487831
[TBL] [Abstract][Full Text] [Related]
10. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers.
Miettinen M; Fernandez M; Franssila K; Gatalica Z; Lasota J; Sarlomo-Rikala M
Am J Surg Pathol; 2001 Feb; 25(2):205-11. PubMed ID: 11176069
[TBL] [Abstract][Full Text] [Related]
11. Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma.
Samija I; Lukac J; Marić-Brozić J; Kusić Z
Croat Med J; 2004 Apr; 45(2):142-8. PubMed ID: 15103749
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of microphthalmia transcription factor and tyrosinase in angiomyolipoma of the kidney, renal cell carcinoma, and renal and retroperitoneal sarcomas: comparative evaluation with traditional diagnostic markers.
Zavala-Pompa A; Folpe AL; Jimenez RE; Lim SD; Cohen C; Eble JN; Amin MB
Am J Surg Pathol; 2001 Jan; 25(1):65-70. PubMed ID: 11145253
[TBL] [Abstract][Full Text] [Related]
13. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
14. Idiosyncrasies of scalp melanoma.
Rigual NR; Cheney RT; Iwenofu OH; Li Q; Loree TR; Popat SR; Merzianu M
Laryngoscope; 2007 Aug; 117(8):1354-8. PubMed ID: 17592396
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma.
Samija I; Lukac J; Marić-Brozić J; Buljan M; Alajbeg I; Kovacević D; Situm M; Kusić Z
Melanoma Res; 2010 Aug; 20(4):293-302. PubMed ID: 20357686
[TBL] [Abstract][Full Text] [Related]
16. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
17. Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful?
Karimipour DJ; Lowe L; Su L; Hamilton T; Sondak V; Johnson TM; Fullen D
J Am Acad Dermatol; 2004 May; 50(5):759-64. PubMed ID: 15097961
[TBL] [Abstract][Full Text] [Related]
18. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
Plótár V; Szentirmay Z; Orosz Z
Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
[TBL] [Abstract][Full Text] [Related]
19. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
